As of September 30, 2023, the Company had cash of $2.4 million, compared to $10.4 million as of December 31, 2022. “The third quarter marked a particularly progressive time at Bio-Path as we reported compelling clinical data from our Phase 2 trial of prexigebersen in acute myeloid leukemia,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “In October, we hosted a Key Opinion Leader event with two physician experts who expressed their enthusiasm for the potential of prexigebersen to change the treatment landscape and patient outcomes in this most challenging patient population.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BPTH:
- Bio-Path Holdings Reports Third Quarter 2023 Financial Results
- Is BPTH a Buy, Before Earnings?
- Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
- Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
- Biotech Alert: Searches spiking for these stocks today